Market Trends of Gonorrhea Therapeutics Industry
This section covers the major market trends shaping the Gonorrhea Therapeutics Market according to our research experts:
Dual Therapy Segment is Expected to Register a Significant Growth Over the Forecast Period.
The dual therapy segment is expected to witness significant growth over the forecast period owing to the increasing number of gonorrhea cases caused by Neisseria gonorrhoeae and the efficacy of dual therapy in the treatment of this disease. Dual therapy with ceftriaxone and azithromycin is recommended as the first-line regimen for the treatment of gonorrhea. Also, in 2021, WHO will recommend dual therapy over monotherapy for people with symptomatic and asymptomatic gonorrhea. Thus, the increasing use of dual therapy treatments is driving the growth of this segment.
Many clinical studies and research have also concluded that dual therapy is more effective in gonorrhea treatment as compared to monotherapy. For example, an article published in the November 2021 issue of the Journal of Infectious Diseases reported that the European Union against Sexually Transmitted Infections had implemented dual therapy for gonorrhea (azithromycin and ceftriaxone) for gonorrhea treatment.
Similarly, another article published in the journal Clinical Infectious Diseases in October 2021 reported the efficacy of dual therapy for the treatment of gonorrhea infections. The article also quoted the evidence on the efficacy of high-dose ceftriaxone monotherapy for extragenital Neisseria gonorrhoeae (NG) infection. Thus, increasing the efficacy of dual therapy in the treatment of gonorrhea is driving the growth of this segment.
Thus, the increasing efficacy of dual therapy for gonorrhea treatment is driving the growth of this segment over the forecast period, thereby driving the market.
North America is Estimated to Register a Significant Growth Over the Forecast Period.
The North American region is expected to witness significant growth over the forecast period owing to the high standards of healthcare infrastructure and the easy availability of sophisticated technology in this region. As per CDC estimates, in September 2022, the Center for Disease Control and Prevention (CDC) reported that in 2021, in the United States, 6,94,796 cases of gonorrhea were reported, and this number increased by 25.4% in the last four years. The United States reported a higher number of gonorrhea cases in men than in women.
Further, recent developments such as mergers, acquisitions, product launches, and partnerships among key market players are also propelling the growth of the studied market. In March 2022, Evofem Biosciences, Inc. announced that it had completed enrollment in EVOGUARD, the registrational Phase 3 clinical trial evaluating EVO100 for two potential new indications: the prevention of chlamydia infection in women and the prevention of urogenital gonorrhea infection in women. Thus, the search for new product launches provides better therapeutics to patients, contributing to the growth of the region's studied market.
Similarly, the government initiatives in the region for the effective control of STDs like gonorrhea are also driving the growth of the studied market. For instance, in August 2022, the American Medical Association launched the creation of a toolkit for the nation's physicians to promote screening of STIs that included HIV, gonorrhea, viral hepatitis, and latent tuberculosis. Also, in July 2022, the National Strategic Plan aims to reverse the recent dramatic rise in STIs in the United States. The STI plan aims to provide a roadmap for a broad range of stakeholders, including public health, health care, government, community-based organizations, educational institutions, researchers, private industry, and academia, to develop, enhance, and expand STI prevention and care programs at the local, state, tribal, and national levels over the next five years. The diseases covered in this plan include secondary syphilis, congenital syphilis, gonorrhea, human papillomavirus, chlamydia, etc.
Thus, due to the high standards of healthcare infrastructure and the easy availability of sophisticated technology and technological developments, the region is expected to witness significant growth over the forecast period.
